XML 59 R48.htm IDEA: XBRL DOCUMENT v3.26.1
Note 9 - License Agreements (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 171 Months Ended
Feb. 23, 2026
Feb. 10, 2025
Jan. 07, 2025
Jan. 07, 2024
Jul. 28, 2023
Feb. 28, 2026
Jun. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Jan. 31, 2012
Precision BioSciences, Inc. [Member]                      
Investment Purchased Balance Shares (in shares)     220,712                
License Agreement, Percentage of Premium on Equity Investment 200.00%                    
License Agreement, Share Price, Trading Days (Day) 30 years   30 days                
License Agreement, Payment, Percentage of Weighted Average Share Price     200.00%                
Precision BioSciences, Inc. [Member] | Maximum [Member]                      
Investment Purchased Balance Shares (in shares) 201,504     2,920,816              
Product [Member]                      
Accounts Receivable, after Allowance for Credit Loss             $ 29,200 $ 29,200   $ 16,100  
L F B License Agreement [Member]                      
License And Collaboration Agreement, Expenses Incurred                 $ 31,000    
Accounts Payable                 $ 0    
Royalty Expense             24,400 45,000      
Accrued Royalties             24,300 24,300      
L F B License Agreement [Member] | License Agreement Terms [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year)                     15 years
Commercialization Agreement With Neuraxpharm [Member]                      
License and Collaboration Agreements, One-time, Non-refundable Payment         $ 140,000     445,300      
Additional Amount Receivable on Achievement of Pre-specified Milestones         $ 492,500            
Royalty Percentage on Net Product Sales         30.00%            
Revenues             3,600 6,300      
Deferred Revenue             31,400 31,400      
Accounts Receivable, after Allowance for Credit Loss             $ 3,600 $ 3,600      
Briumvi Ublituximab [Member] | Product [Member]                      
Product Sales, Net Related to Performance Obligations         $ 12,500            
Precision License Agreement [Member]                      
Additional Amount Receivable on Achievement of Pre-specified Milestones           $ 286,000          
License Agreement, Amount Paid Upfront $ 7,500     $ 7,500   7,500          
License Agreement, Amount Paid Upfront, Cash 5,250     5,250   5,250          
License Agreement, Amount Paid Upfront, Equity Investment $ 2,250     2,250   $ 2,250          
License Agreement, Deferred Payment       $ 2,500              
License Agreement, Percentage of Premium on Equity Investment       100.00%              
License Agreement, Share Price, Trading Days (Day)       30 days   30 days          
License Agreement, Payment, Percentage of Weighted Average Share Price           200.00%          
Term After First Commercial Sale (Year)           10 years          
Precision License Agreement [Member] | Maximum [Member]                      
Investment Purchased Balance Shares (in shares)           201,504          
Strategic Platform License Agreement with MaxCyte, Inc. [Member]                      
License Agreement, Amount Paid Upfront   $ 1,000                  
License Agreement, Additional Milestone Payments   13,000                  
Licensing Agreement, Annual License Fee   $ 200                  
License Agreement, Term (Year)   10 years                  
License Agreement, Renewal Term (Year)   5 years                  
License Agreement, Written Notice Period (Day)   90 days